Source:http://linkedlifedata.com/resource/pubmed/id/19744223
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-5-11
|
| pubmed:databankReference | |
| pubmed:abstractText |
SUMMARY: The aim of this study was to compare the long-term safety and efficacy of immunosuppressive regimens consisting of cyclosporine (CsA) plus mycophenolate mofetil (MMF) or tacrolimus (TAC) plus MMF after steroid withdrawal 6 months after kidney transplantation in low-risk patients. One hundred and thirty-one patients were randomized to receive either CsA (n = 63) or TAC (n = 68). Of these, 117 patients satisfied the criteria for steroid withdrawal (no biopsy-proven rejection episode and serum creatinine level <2.0 mg/dl 6 months after transplantation). Fifty-five recipients were of the CsA group, and 62 were of the TAC group. The 5-year graft survival rate did not differ between groups (90.5% vs. 93.3% respectively; P = 0.55). The cumulative incidence of acute rejection 5 years after transplantation was 16.4% and 8.1% for the CsA and TAC groups respectively (P = 0.15). Post-transplantation diabetes mellitus was more frequent in the TAC group than in the CsA group (P = 0.05), but the incidence of other side-effects did not differ between groups. In conclusion, CsA- and TAC-based regimens in conjunction with MMF have similar patient- and graft survival rates in low-risk patients who underwent steroid withdrawal 6 months after kidney transplantation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclosporine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Mycophenolic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Steroids,
http://linkedlifedata.com/resource/pubmed/chemical/Tacrolimus,
http://linkedlifedata.com/resource/pubmed/chemical/mycophenolate mofetil
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
1432-2277
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
23
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
147-54
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19744223-Adult,
pubmed-meshheading:19744223-Cyclosporine,
pubmed-meshheading:19744223-Diabetes Mellitus,
pubmed-meshheading:19744223-Female,
pubmed-meshheading:19744223-Follow-Up Studies,
pubmed-meshheading:19744223-Graft Rejection,
pubmed-meshheading:19744223-Graft Survival,
pubmed-meshheading:19744223-Humans,
pubmed-meshheading:19744223-Immunosuppressive Agents,
pubmed-meshheading:19744223-Kaplan-Meier Estimate,
pubmed-meshheading:19744223-Kidney Transplantation,
pubmed-meshheading:19744223-Living Donors,
pubmed-meshheading:19744223-Male,
pubmed-meshheading:19744223-Middle Aged,
pubmed-meshheading:19744223-Mycophenolic Acid,
pubmed-meshheading:19744223-Prospective Studies,
pubmed-meshheading:19744223-Steroids,
pubmed-meshheading:19744223-Tacrolimus
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up.
|
| pubmed:affiliation |
Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|